Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 2Spinal Cord Neoplasms 1Sarcoma, Kaposi 1Optic Nerve Glioma 1Oligodendroglioma 1Neurofibromatosis 2 1Neurofibromatoses 1Neoplasms by Histologic Type 1Meningioma 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1HIV Infections 1Familial ependymoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1AIDS-related Kaposi sarcoma 1

Interventions

Bevacizumab 5Everolimus 4Sirolimus 2Lapatinib 2HDAC-42 2vistusertib 1temsirolimus 1neratinib 1icotinib 1emvododstat 1brolucizumab 1brigatinib 1aflibercept 1Vascular Endothelial Growth Factor A 1Valproic Acid 1Sunitinib 1Magnetic Resonance Imaging 1Immunoglobulin G 1Endostatins 1Doxycycline 1Disulfides 1Crizotinib 1Cetuximab 1Axitinib 1Aspirin 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neurofibromatosis 2 × emvododstat × Clear all
NCT00911248 2019-04-12

PTC299 for Treatment of Neurofibromatosis Type 2

PTC Therapeutics

Phase 2 Terminated
11 enrolled
CNS

Neurofibromatosis 2, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon âš¡